Skip to main content
. 2022 Jul 15;25(2):339–350. doi: 10.1093/neuonc/noac173

Fig. 3.

Fig. 3

Overall and progression-free survival by EGFRvIII mutation. Overall (a, c) and progression-free survival (b, d; by central review) by treatment arm for patients with (a, b) or without (c, d) EGFRvIII mutation on an intent-to treat basis. The number of patients at risk over time is shown below the curves. HR, Hazard ratio (with 95% confidence intervals).